VIVO News and Press, Meridian Bioscience Inc. From 11/13/20

The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Meridian Bioscience, Inc. 2020 Q4 - Results - Earnings Call Presentation

Meridian Bioscience (VIVO): Q4 Non-GAAP EPS of $0.19 beats by $0.05; GAAP EPS of $0.15 beats by $0.01.Revenue of $64.15M (+26.2% Y/Y) beats by $4.68M.Press Release For further details see: Meridian Bioscience EPS beats by $0.05, beats on revenue

CINCINNATI, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highlights (Comparison to Fourth Quarter Fiscal 2019): Consolidated N...

Company is hitting it out of the park in its Life Science segment. Market has already discounted this as we can see from the technical chart. We need to see improvement in Diagnostics soon to keep its present valuation. For further details see: Meridian Bioscience: Remai...

The best sectors to focus your attention on now. The highest-rated stocks worth adding to your watch list. Why high-volatility ahead of elections could create a great buy opportunity. For further details see: If Stocks Tumble On Election Worries, Here Are The Top Stocks ...

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2020 financial results Friday, November 13, 2020. Jack Kenny, Chief Executive Off...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: Healthcare: XLV Survey For October

CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing ...

Gainers: [[JAX]] +4.5%. [[AXGT]] +4.4%. [[HRI]] +3.1%. [[AVDL]] +2.3%. [[AAL]] +1.7%.Losers: [[TATT]] -6.2%. [[FNKO]] -3.5%. [[IMGN]] -3.0%. [[VIVO]] -2.6%. [[INMD]] -1.6%. For further details see: AXGT, AVDL, INMD and IMGN among after-hours movers

The following slide deck was published by Meridian Bioscience, Inc. in conjunction with this Read more ...